Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

RAPT Therapeutics, Inc. RAPT NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
25/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$30.71
-47.1%

RAPT Therapeutics, Inc. (RAPT) is a Biotechnology company in the Healthcare sector, currently trading at $58.01. It has a SharesGrow Score of 24/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is RAPT = $31 (-47.1% upside).

Net income is $130M (loss), growing at -24.6%/yr. Net profit margin is 0% (thin). Gross margin is -83.8% (-157.7 pp trend).

Balance sheet: total debt is $4M against $190M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.87 (strong liquidity). Debt-to-assets is 1.9%. Total assets: $240M.

Analyst outlook: 4 / 15 analysts rate RAPT as buy (27%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 6/100 (Fail), Future 16/100 (Fail), Income ?/100 (Fail).

$30.71
▼ 47.06% Downside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for RAPT Therapeutics, Inc., the average price target is $30.71, with a high forecast of $55.00, and a low forecast of $2.00.
Highest Price Target
$55.00
Average Price Target
$30.71
Lowest Price Target
$2.00

RAPT SharesGrow Score Overview

29/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 6/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RAPT

✗
VALUE Fail
10/100
RAPT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $31, implying -46.6% from the current price $58. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
RAPT: -80%/yr revenue is, -24.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet RAPT: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 4.87 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
6/100
RAPT: Gross margin is -83.8% (-157.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 6/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 4 / 15 analysts rate RAPT as buy (27%). Analyst consensus target is $31 (-46.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range5.6652-58.02
Volume10.85M
Avg Volume (30D)2.34M
Market Cap$959.26M
Beta (1Y)0.44
Share Statistics
EPS (TTM)-3.19
Shares Outstanding$40.76M
IPO Date2019-10-31
Employees67
CEOBrian Russell Wong
Financial Highlights & Ratios
EBITDA$-126.33M
Net Income$-129.87M
Operating Income$-136.1M
Total Cash$231.06M
Total Debt$4.49M
Net Debt$-165.24M
Total Assets$240.33M
Price / Earnings (P/E)-18.2
Analyst Forecast
1Y Price Target$33.00
Target High$55.00
Target Low$2.00
Upside-43.1%
Rating ConsensusHold
Analysts Covering15
Buy 27% Hold 73% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS75382E2081

Price Chart

Track all markets on TradingView
RAPT
RAPT Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
5.67 52WK RANGE 58.02

People Also View

RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message